BOULS Stock Overview
Develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
+ 1 more risk
Boule Diagnostics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 26.30 |
| 52 Week High | SEK 37.80 |
| 52 Week Low | SEK 26.30 |
| Beta | 0.82 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -56.39% |
| 5 Year Change | -59.92% |
| Change since IPO | 33.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| BOULS | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 2.2% |
| 1Y | n/a | -2.4% | 8.8% |
Return vs Industry: Insufficient data to determine how BOULS performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how BOULS performed against the UK Market.
Price Volatility
| BOULS volatility | |
|---|---|
| BOULS Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BOULS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BOULS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 200 | Jesper Soderqvist | www.boule.com |
Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. The company provides hematology analyzers, reagents, blood controls and calibrators, and reagents rotors, as well as cleaning products under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer and diagnostics systems under the Exigo brand. It sells its products directly in Sweden and the United States, as well as through distributors internationally.
Boule Diagnostics AB (publ) Fundamentals Summary
| BOULS fundamental statistics | |
|---|---|
| Market cap | SEK 310.66m |
| Earnings (TTM) | SEK 31.87m |
| Revenue (TTM) | SEK 525.34m |
9.7x
P/E Ratio0.6x
P/S RatioIs BOULS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOULS income statement (TTM) | |
|---|---|
| Revenue | SEK 525.34m |
| Cost of Revenue | SEK 307.51m |
| Gross Profit | SEK 217.84m |
| Other Expenses | SEK 185.96m |
| Earnings | SEK 31.87m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 10, 2022
| Earnings per share (EPS) | 1.64 |
| Gross Margin | 41.47% |
| Net Profit Margin | 6.07% |
| Debt/Equity Ratio | 62.6% |
How did BOULS perform over the long term?
See historical performance and comparison